Ignite Creation Date:
2024-05-06 @ 7:41 PM
Last Modification Date:
2024-10-26 @ 3:11 PM
Study NCT ID:
NCT06092086
Status:
RECRUITING
Last Update Posted:
2023-10-23
First Post:
2023-07-21
Brief Title:
Lorlatinib as the First-line Treatment in China Advanced ALK NSCLC
Sponsor:
Guangdong Association of Clinical Trials
Organization:
Guangdong Association of Clinical Trials
Organization Data
Organization:
Guangdong Association of Clinical Trials
Class:
OTHER
Study ID:
CTONG2203
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Guangdong Association of Clinical Trials
Lead Sponsor Class:
OTHER
Responsible Party:
Yi-Long Wu
Responsible Party Title:
Principal Investigator
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Guangdong Association of Clinical Trials
Old Name:
None
Old Organization:
None